Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Mesenchymal stem cell therapy | 2 |
Inactivated vaccine | 1 |
Diagnostic radiopharmaceuticals | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism UBASH3B inhibitors |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date28 Sep 1990 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Stem cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date31 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Start Date15 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Inactivated whole virus influenza vaccine(KM Biologics KK) | Influenza, Human More | Phase 2 Clinical |
HUFF-01 | Cerebral Hemorrhage More | Phase 2 Clinical |
P-gp and/or MRP1 inhibitors(Hokkaido University) ( MRP1 x P-gp ) | Inflammation More | Preclinical |
GCT-102 | Fractures, Ununited More | Preclinical |
123I-IIMU ( TYMP ) | Neoplasms More | Preclinical |